A practical approach to accurate classification and staging of mycosis fungoides and sézary syndrome.

A practical approach to accurate classification and staging of mycosis fungoides and sézary syndrome. Skin Therapy Lett. 2012 Dec;17(10):5-9 Authors: Thomas BR, Whittaker S Abstract Cutaneous T-cell lymphomas are rare, distinct forms of non-Hodgkin´s lymphomas. Of which, mycosis fungoides (MF) and Sézary syndrome (SS) are two of the most common forms. Careful, clear classification and staging of these lymphomas allow dermatologists to commence appropriate therapy and allow correct prognostic stratification for those patients affected. Of note, patients with more advanced disease will require multi-disciplinary input in determining specialist therapy. Literature has been summarized into an outline for classification/staging of MF and SS with the aim to provide clinical dermatologists with a concise review. PMID: 23223768 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. Yale J Biol Med. 2020 Mar;93(1):41-44 Authors: Hu JK, Carlson K, Girardi M Abstract Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is characterized by malignant CD4+ skin-homing T-cells that drive formation of cutaneous patches, plaques, and/or tumors. MF's known immunogenicity makes it an ideal candidate for local immunotherapy. Recombinant human leukocyte interferon-α2 (rIFN-α2) has well-established immunomodulatory, antiproliferative, and antitumor effects; an...
Source: The Yale Journal of Biology and Medicine - Category: Universities & Medical Training Tags: Yale J Biol Med Source Type: research
We report here a high response rate using a novel therapeutic regimen combining interferon gamma, isotretinoin in low dose and topical carmustine, and in some cases concomitant skin-directed therapies, among 6 consecutive patients with refractory folliculotropic mycosis fungoides with stages IB through IIIB who had previously failed both topical and systemic therapies. The potential mechanisms of this multimodality approach are discussed. PMID: 32128597 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
Mycosis Fungoides (MF) is an indolent extranodal T-cell lymphoma that presents with a variable combination of waxing and waning cutaneous symptoms (scaly rash, pruritus, burning, and sometimes pain).[1] The chronic nature of the skin symptoms and the burden of carrying a diagnosis of malignancy have significant impact on the quality of life of MF patients. Health-related quality of life (HRQoL), quantified via several available questionnaires, generally is poor in patients with MF [2 –5] though we lack an in depth understanding of the specific factors that influence it, especially in subgroups of MF patients with early stage disease.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research
To the Editor: Mechlorethamine (ie, nitrogen mustard) is a skin-directed therapy (SDT) for mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL) used since the mid-1900s, with response rates of 70% to 80%.1-3 Mechlorethamine gel (MG) 0.016% (Valchlor; Helsinn Therapeutics, Iselin, NJ) was United States Food and Drug Administration approved in 2013 (stages IA/IB). PROVe (A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor ®, ClinicalTrials.gov identifier: N...
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Letter Source Type: research
ConclusionWe found hypopigmented MF to be the most common clinical presentation in patients under 18 years of age. The disease did not progress to advanced stages in any of the patients, although recurrence after treatment interruption was common.ResumenAntecedentesLa micosis fungoide (MF) es el tipo más común de linfoma cutáneo de células T tanto en adultos como en niños. En algunos países se ha observado un aumento de la prevalencia de MF en niños. Hasta la fecha, no existen estudios descriptivos de MF en la población pediátrica colombiana.MétodosEn un...
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Source Type: research
Cutaneous T-cell lymphoma (CTCL) was a highly heterogeneous non-Hodgkin lymphomas characterized by the residing of malignant T lymphocytes in the lesions of skin [1]. The incidence of CTCL was 6.4 per million, which made it the second most common extra-nodal non-Hodgkin lymphomas [2]. Mycosis fungoides (MF) and S ézary syndrome (SS) were the most common form of CTCL, both of them accounted for more than 80% of CTCL, and MF was the main form of CTCL [2–4]. Owning to the heterogeneity and the scarcity of special targets, the precise treatment of CTCL also met huge challenges.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research
Cutaneous T cell lymphomas represent a heterogenous group of lymphoproliferative disorders defined by clonal proliferation of T cells present in the skin. The latest WHO classification in 2016 and WHO-EORTC classification in 2018 has updated the classification of these entities based on the molecular profile. Research in the field of molecular genetics of CTCL has allowed a better understanding of the biology of these tumors and has helped to identify potential targets for therapy that can be tailored to individual patients. In this review, we discuss the latest developments in the molecular profile of CTCLs including biom...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Montserrat Molgó, Leonardo Espinoza-Benavides, Patricio Rojas, Sergio GonzálezIndian Journal of Dermatology 2020 65(1):57-60 A 59-year-old man with Hodgkin's lymphoma was referred by a hematologist for consultation for cutaneous issues. Physical examination revealed generalized scaling and erythematous scaly patches located in the groin, abdomen, and arms. The biopsy was compatible with mycosis fungoides (MF). At his next medical visit, painful nodules with erythematous halo and scabby surface were noted, and a subsequent biopsy was compatible with lymphomatoid papulosis (LyP). Mycosis fungoides, the most co...
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Condition:   Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB) Intervention:   Drug: chlormethine gel Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cutaneous T cell lymphoma | Dermatology | Lymphoma | Mycosis Fungoides | Skin | T-cell Lymphoma